New hope for children with thalassaemia

An international group of EU-funded researchers has investigated the safety and efficacy of using the drug deferiprone to treat children with the blood disorder beta-thalassaemia major. The news is good.

Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Brazil
  Bulgaria
  Burkina Faso
  Cambodia
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czechia
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Faroe Islands
  Finland
  France
  French Polynesia
  Georgia

Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Brazil
  Bulgaria
  Burkina Faso
  Cambodia
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czechia
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Faroe Islands
  Finland
  France
  French Polynesia
  Georgia


 

Published: 1 June 2018  
Related theme(s) and subtheme(s)
Health & life sciencesDrugs & drug processes  |  Medical research  |  Public health
International cooperation
Research policySeventh Framework Programme
Countries involved in the project described in the article
Canada  |  Egypt  |  Germany  |  Greece  |  Italy  |  Netherlands  |  Tunisia
Add to PDF "basket"

New hope for children with thalassaemia

Image

© Photographee.eu #70748737, 2018. Source: fotolia.com

Children born with thalassaemia, a genetic blood disease, cannot create normal haemoglobin, which is needed to produce healthy red blood cells. Regular blood transfusions are the only treatment available, but iron overload is inevitable.

Since iron accumulation can cause potentially fatal multi-organ dysfunction, transfusion therapy is coupled with iron chelation – the removal of excess iron from the blood via special drugs. Deferiprone (DFP) – authorised in Europe in 1999 – is considered very effective, but it has remained second in line and in fact discouraged for treating children under the age of six due to a scarcity of studies involving paediatric patients.

297 patients, 16 hospitals, 6 countries

This is where the independent consortium DEEP (Deferiprone Evaluation in Paediatrics) stepped in. Born from the TEDDY Network – an EU-funded Network of Excellence, the DEEP project has already provided evidence confirming the safe dosage for use without risk in children (DEEP-1 clinical trial results). It also led to the development of a new oral liquid formulation of DFP suitable for the paediatric use (including in babies from the first month), to be administered in that dose. The complete panel of the drug activities, efficacy and safety will be available soon (DEEP-2 clinical trial).

The DEEP Project also investigated the long-term safety of DFP therapy in children suffering from beta-thalassaemia major, which unfortunately requires lifelong treatment (DEEP-3 observational study). DEEP 3 was a cohort study conducted in 16 hospitals in six Mediterranean countries (Albania, Cyprus, Egypt, Greece, Italy and Tunisia) between November 2012 and April 2016. A total of 297 patients were enrolled and observed.

‘Remarkable’

For Amal El-Beshlawy, chair of the Egyptian Thalassemia Association, the project’s findings are “remarkable”.

The Egyptian member of the DEEP consortium, El-Beshlawy is quick to note the project’s importance – especially for her country. “Thalassemia is a major health concern in Egypt,” she says. “The prevalence of disease carriers is nearly 9%, one of the highest rates worldwide. For every 1.5m children born in Egypt annually, almost 1 000 carry the disease.”

El-Beshlawy has been working hard to shed light on this disease, and is pleased that Egypt has been at the forefront of efforts to find the best treatment for children.

“The DEEP project…is crucial for the life of young patients with thalassaemia. Iron overload can kill. The treatment is lifesaving.”

Such far-reaching international cooperation, involving so many countries from Europe and North Africa, is unrivalled, says El-Beshlawy. “It has been a real success because treating this disease is very important in all these countries. It has been a great experience and a big advantage to be part of this global cooperation.’

According to El-Beshlawy, the project’s impact will be huge for patients in Egypt and other countries struggling with a particularly high prevalence of thalassaemia. “Many lives will be saved.”

Project details

  • Project acronym: DEEP
  • Participants: Italy (Coordinator), Cyprus, Germany, Greece, the Netherlands, Albania, Canada, Egypt, Tunisia
  • Project N°: 261483
  • Total costs: € 7 626 002
  • EU contribution: € 5 262 963
  • Duration: January 2011 to August 2016

See also

 

Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also
Project website
Project details